Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Roberto Leon-Ferre

Breast Oncology · Mayo Clinic College of Medicine

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View

Dr. Neil Iyengar

Breast Oncology · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.

    Aug 23, 2025DOI: 10.1245/s10434-025-17933-2Journal ArticleASO

    Written by: Julie Van HasselKatrina DimitroffChristina YauRita MukhtarJudy C BougheyVelle LadoresMarissa M Howard-McNattNora JaskowiakJane PerlmutterAngela DeMicheleDouglas YeeNola HyltonW Fraser SymmansLaura Van't VeerHope RugoLaura J EssermanRebecca ShatskyClaudine IsaacsHenry KuererAnne M WallaceNicolas PrionasJennifer TsengChantal R ReynaNeil TaunkSusan KesmodelMarie C LeeJana FoxMara A PiltinJulia TchouCletus A ArcieroLauren M PostlewaitCandice SauderRoshni Rao

    Find these authors on Roon

    LE

    Dr. Laura Esserman

    Breast Surgical Onc · UCSF Medical Center

    RS

    Dr. Rebecca Shatsky

    Breast Oncology · UCSD

    CR

    Dr. Chantal Reyna

    Breast Surgical Onc · Foster G. McGaw Hospital

    CA

    Dr. Cletus Arciero

    Breast Surgical Onc · Emory University

    Summary

    BACKGROUND: Neoadjuvant chemotherapy (NAC) is widely used to treat high-risk breast cancer. However, the optimal time to surgery (TTS) following NAC remains undefined. This study investigates the impact of TTS on oncologic outcomes using the I-SPY 2 Trial cohort.METHODS: A retrospective analysis of 1877 patients with breast cancer enrolled in the I-SPY 2 Trial was performed. Patients were grouped by TTS post-NAC: 1-4 weeks, 5 weeks, 6-8 weeks, and 9 + weeks. Baseline demographic, clinical, imaging, and treatment response data were collected. Event-free survival (EFS) and local recurrence-free interval (LRFI) were evaluated using Kaplan-Meier analyses and Cox models. Subgroup analyses were performed by tumor receptor subtypes (hormone receptor [HR]+ human epidermal growth factor receptor 2 [HER2]-, HER2 +, and triple-negative breast cancer [TNBC]) and residual cancer burden (RCB) class.RESULTS: Among 1877 patients, 526 (28.0%) underwent surgery between 1-4 weeks, 425 (22.6%) at 5 weeks, 490 (26.1%) between 6-8 weeks, and 436 (23.2%) at 9+ weeks post-NAC. Prolonged TTS was associated with worse 5-year EFS and LRFI on Kaplan-Meier analysis (p < 0.001 for both). Delays particularly affected outcomes in patients with HR+/HER2- and TNBC tumors. In patients with RCB class II/III, a TTS of 9+ weeks was independently associated with worse EFS (hazard ratio [HR] 2.04, p = 0.001) and LRFI (HR 2.77, p = 0.005). Conversely, in patients with a pathologic complete response/RCB class I, delayed surgery did not significantly impact outcomes.CONCLUSIONS: TTS of 9+ weeks following NAC is independently associated with worse oncologic outcomes, especially in patients with TNBC and HR+/HER2- tumors and high residual disease.
    RSDr. Rebecca Shatsky
    Leading Voice

    Dr. Rebecca Shatsky

    Medical Oncology · Breast Oncology
    University of California San Diego
    rebeccas